By Fineline Cube China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for its Cosela (trilaciclib) at the Jilin Cancer Hospital. This milestone marks the official clinical application of the first-in-class CDK4/6 inhibitor in China.
Drug Background and Development
Trilaciclib, discovered by US biotech G1 Therapeutics Inc., was in-licensed by Simcere in August 2020. The drug received conditional market approval in China in July 2022 for use in adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have not previously received systemic chemotherapy. The Phase III PRESERVE 2 study for trilaciclib completed patient enrollment in October, further supporting its clinical application.
Clinical Application and Future Outlook
The first prescription of Cosela at the Jilin Cancer Hospital signifies the beginning of its clinical use in China. As the first CDK4/6 inhibitor to enter the market, Cosela is poised to address significant unmet needs in the treatment of ES-SCLC, offering a new therapeutic option for patients and healthcare providers.-Fineline Info & Tech